Strain
|
Treatment
|
Disease outcome
|
References
|
(NZB X W)F1
| rIL1 | More severe |
63
|
MRL-lpr
| rIL1R | Beneficial |
93
|
MRL-lpr
| rIL1R antagonist | No effect |
94 |
(NZB X W)F1
| human rIL2 high and low doses | No effect |
20 |
(NZB X W)F1
| Anti-IL2R mAb | Beneficial |
21 |
MRL-lpr
| Vaccinia virus IL2 construct | Beneficial |
17
|
MRL-lpr
|
S typhimurium with IL2 gene | Beneficial |
18
|
MRL-lpr
| IL2 expression vector injected IM | More severe |
19 |
(NZB X W)F1
| Anti-IL4 mAb | Beneficial |
44 |
(NZB X W)F1
| Anti-IL4 mAb + Anti-ILl2 mAb | No effect |
44
|
(NZB X W)F1
| rIL6 | More severe |
49 |
(NZB X W)F1
| Anti-IL6 mAb | Beneficial |
50
|
MRL-lpr
| Anti-IL6R mAb | Beneficial |
51 |
(NZB X W)F1
| Anti-IL10 mAb | Beneficial |
54 |
(NZB X W)F1
| Anti-IL10 mAb + Anti-TNFα mAb | No effect |
54 |
(NZB X W)F1
| rIL10 | More severe |
54 |
(NZB X W)F1
| AS101 (IL10 inhibiting immunomodulator) | Beneficial |
55
|
MRL-lpr
| rIL12 | More severe |
41
|
(NZB X W)F1
| Anti-IL12 mAb | Reduced anti-DNA, no effect on GN |
44 |
(NZB X W)F1
| rIFNy | More severe |
31 |
(NZB X W)F1
| Anti-IFNγ mAb | Beneficial |
31 |
(NZB X W)F1
| sIFNγR | Beneficial |
32 |
(NZB X W)F1
| rTNFα low dose (2 mo) | No effect |
63 |
(NZB X W)F1
| rTNFα low dose (4 mo) | More severe |
63
|
(NZB X W)F1
| rTNFα intermediate dose (4 mo) | No effect |
63 |
(NZB X W)F1
| rTNFα high dose administered early | Beneficial |
58, 73, 74 |
(NZB X W)F1
| rTNFα high dose administered late | No effect |
58, 73 |
MRL-lpr
| Anti-TNFα mAb | Beneficial |
75
|
MRL-lpr
| Transcriptional inhibitor of TNFα | Beneficial |
79
|
MRL-lpr
| Anti-TGFß mAb | Beneficial |
97
|
MRL-lpr
|
S typhimurium with TGFß gene | No effect |
18
|
MRL-lpr
| TGF-ß expression vector injected IM | Beneficial |
19
|